GlobeNewswire Inc | Oct 12, 2021 08:30AM EDT

October 12, 2021

BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2021, ended September 30, 2021. The webcast and conference call will be held at8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time onOctober 26, 2021.

Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovants website atinvestors.myovant.com. Institutional investors and analysts may also participate in the conference call by dialing 1-800-532-3746 in theU.S.or+1-470-495-9166 from outside theU.S.

A replay of the webcast, along with the earnings press release and presentation materials, will be archived on Myovants investor relations website.

AboutMyovant SciencesMyovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.Founded in 2016, we have two FDA-approved products. ORGOVYX(relugolix) was approved by theU.S. Food and Drug Administrationin 2020 as the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and relugolix is also under regulatory review inEuropefor men with advanced prostate cancer.Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) was approved in 2021 in theU.S.as MYFEMBREEas the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, and by theEuropean Commissionas RYEQOfor the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. We have filed a supplemental New Drug Application (sNDA) for the management of moderate to severe pain associated with endometriosis, which was accepted for review by the FDA in September 2021. The therapy is also being assessed for the prevention of pregnancy. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction.Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website atwww.myovant.com. Follow@Myovanton Twitter andLinkedIn.

Investor Contact:Ryan CroweVice President, Investor Relations+1 (650) 781-9106investors@myovant.com

Media Contact:Albert LiaoDirector, Corporate Communications+1 (650) 410-3055media@myovant.com